Heart attack patients may benefit from Clot-Busting drug before delayed procedure

NCT ID NCT07641231

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at 240 adults having a major heart attack (STEMI) when the standard emergency procedure to open the blocked artery is expected to be delayed by over an hour. Half will get a clot-busting drug (tenecteplase) right away, followed by the procedure within 2-24 hours. The other half will just have the standard procedure. The goal is to see if the early drug reduces the risk of death, stroke, or another heart attack within a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tenecteplase
What this could lead to
If successful, this could show that giving a clot-busting drug early, even when a hospital can do a standard procedure, improves survival and reduces complications after a heart attack.
What could go wrong
This is a Phase 4 study with only 240 participants, so results may not apply to everyone. The clot-busting drug also increases bleeding risk, which could offset any benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEMI - ST ELEVATION MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

    Moscow, Select A State, 121552, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.